Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.58 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228615 | 1.00 | AQP1 (0.58) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5185008 | 0.90 | AQP1 (0.57) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4224942 | 0.87 | AQP1 (0.72) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4223679 | 0.87 | AQP1 (0.72) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4222332 | 0.87 | AQP1 (0.76) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4368897 | 0.86 | AQP1 (0.48) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4368891 | 0.86 | AQP1 (0.48) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4230245 | 0.85 | AQP1 (0.62) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4224838 | 0.84 | AQP1 (0.79) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5187644 | 0.84 | AQP1 (0.65) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1802598-A2 | ASYMMETRIC SYNTHESIS OF DIHYDROBENZOFURAN DERIVATIVES | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006047288-A2 | ASYMMETRIC SYNTHESIS OF DIHYDROBENZOFURAN DERIVATIVES | WYETH (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089405-A1 | Asymmetric synthesis of dihydrobenzofuran derivatives | WYETH (US) | 2006-04-27 | — | — | US | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | HTR2C, HTR1A, HTR3A | AQP1 1105/4885PRKAB2 2598/4885PRKAG1 2441/4885 |
| US-20060089405-A1 | Asymmetric synthesis of dihydrobenzofuran derivatives | DHFR, DHODH, DPYD | AQP1 2577/4885PRKAB2 3831/4885PRKAG1 4373/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | AQP1 1105/4885PRKAB2 2598/4885PRKAG1 2441/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | AQP1 2290/4885PRKAB2 2184/4885PRKAG1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.